Pipeline
We are building a robust pipeline of transformative medicines addressing cancer, inflammatory and autoimmune diseases, and fibrosis.
We are building a robust pipeline of transformative medicines addressing cancer, inflammatory and autoimmune diseases, and fibrosis.
Using our Deep Biology platform, we are advancing multiple large molecule therapeutic candidates with the potential to be first-in-class therapeutics. Our most advanced product candidates are outlined in the chart below:
Lead Optimization
Lead Optimization
Hit-to-Lead
Hit-to-Lead
Hit-to-Lead
Target ID & Validation
*In collaboration with Eli Lilly
Lead Optimization
*Partnered with Eli Lilly.
In addition to these therapeutic programs, we are developing a broad research pipeline by applying our Deep Biology Platform, identifying novel insights into tissue immune-regulation to drive target identification.
We have established a number of collaborations and partnerships with leading industry and academic institutions. Notably, we work with Eli Lilly across 4 programs that have been identified and characterized leveraging TRex’s Deep Biology platform : TRB-031, TRB-041, TRB-051 and TRB-052. In December 2021 we entered into a collaboration with Janssen Pharmaceutica NV for novel targets in Immunology & Inflammation.